MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploi...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2023-10-01
Saila:Cell Reports
Gaiak:
CP: Cancer
CP: Metabolism
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S2211124723012330

Internet

http://www.sciencedirect.com/science/article/pii/S2211124723012330

Antzeko izenburuak